Where Regeneron Pharmaceuticals Stands With Analysts
Portfolio Pulse from Benzinga Insights
Regeneron Pharmaceuticals (NASDAQ:REGN) has received a mix of bullish and indifferent ratings from 19 analysts over the last quarter. The average price target is $910.53, indicating an upside from the current price of $822.79. This average has increased by 6.57% from the previous average price target of $854.43.
November 09, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron Pharmaceuticals has received mixed ratings from analysts, with an average price target indicating potential upside.
The mixed ratings from analysts indicate uncertainty about the company's performance. However, the average price target, which is higher than the current price, suggests that analysts see potential for the stock's price to increase. This could have a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100